Frugivory and seed dispersal by the yellow-throated marten (Martes flavigula), in a subtropical forest of China

The yellow-throated marten, Martes flavigula, is the only living species of the genus Martes found in subtropical and tropical forests (Harrison et al. 2004). It is distributed throughout central and southern Asia in a wide variety of habitats. Despite its extensive geographical range, the ecology and behaviour of this species has so far received little attention, aside from a study of habitat use (Grassman et al. 2005). Studies on other martens have shown that fruits are an important food resource (e.g. M. martes, Bermejo & Guitian 2000; M. foina, Pandolfi et al. 1996). Thus, they are considered to be important potential seed dispersers (Corlett 1998, Herrera 1989, Willson 1993), as confirmed by recent studies (M. melampus, Otani 2002; M. americana, Hickey et al. 1999; M. foina and M. martes, Schaumann & Heinken 2002). Although no systematic study of the diet of M. flavigula has been conducted (Harrison et al. 2004), it is known to be omnivorous and to consume fruit (Gao & Wang 1987). To date, however, there has been no comprehensive study of frugivory and seed dispersal by M. flavigula (but see Corlett 1998)

The Implementation of Recommender Systems for Mental Health Recovery Narratives: Evaluation of Use and Performance

Background:Recommender systems help narrow down a large range of items to a smaller, personalized set. NarraGive is a first-in-field hybrid recommender system for mental health recovery narratives, recommending narratives based on their content and narrator characteristics (using content-based filtering) and on narratives beneficially impacting other similar users (using collaborative filtering). NarraGive is integrated into the Narrative Experiences Online (NEON) intervention, a web application providing access to the NEON Collection of recovery narratives.Objective:This study aims to analyze the 3 recommender system algorithms used in NarraGive to inform future interventions using recommender systems for lived experience narratives.Methods:Using a recently published framework for evaluating recommender systems to structure the analysis, we compared the content-based filtering algorithm and collaborative filtering algorithms by evaluating the accuracy (how close the predicted ratings are to the true ratings), precision (the proportion of the recommended narratives that are relevant), diversity (how diverse the recommended narratives are), coverage (the proportion of all available narratives that can be recommended), and unfairness (whether the algorithms produce less accurate predictions for disadvantaged participants) across gender and ethnicity. We used data from all participants in 2 parallel-group, waitlist control clinical trials of the NEON intervention (NEON trial: N=739; NEON for other [eg, nonpsychosis] mental health problems [NEON-O] trial: N=1023). Both trials included people with self-reported mental health problems who had and had not used statutory mental health services. In addition, NEON trial participants had experienced self-reported psychosis in the previous 5 years. Our evaluation used a database of Likert-scale narrative ratings provided by trial participants in response to validated narrative feedback questions.Results:Participants from the NEON and NEON-O trials provided 2288 and 1896 narrative ratings, respectively. Each rated narrative had a median of 3 ratings and 2 ratings, respectively. For the NEON trial, the content-based filtering algorithm performed better for coverage; the collaborative filtering algorithms performed better for accuracy, diversity, and unfairness across both gender and ethnicity; and neither algorithm performed better for precision. For the NEON-O trial, the content-based filtering algorithm did not perform better on any metric; the collaborative filtering algorithms performed better on accuracy and unfairness across both gender and ethnicity; and neither algorithm performed better for precision, diversity, or coverage.Conclusions:Clinical population may be associated with recommender system performance. Recommender systems are susceptible to a wide range of undesirable biases. Approaches to mitigating these include providing enough initial data for the recommender system (to prevent overfitting), ensuring that items can be accessed outside the recommender system (to prevent a feedback loop between accessed items and recommended items), and encouraging participants to provide feedback on every narrative they interact with (to prevent participants from only providing feedback when they have strong opinions)

Characterizing Patients using Abuse-deterrent Formulations of Extended-release Opioid Analgesics

Background: Abuse-deterrent formulations (ADFs) of extended-release (ER) opioids are manufactured to address opioid abuse. However, little is known about characteristics of patients who initiate ADF opioids, which is important to identify appropriate comparators to address confounding by indication. Objectives: To describe demographics and medical characteristics of patients prescribed ADF and non-ADF ER opioids in two sources of commercial claims. Methods: Using IBM Marketscan commercial claims (Data A) and a large private insurance provider in North Carolina [USA] (Data B) (both 2009-2018), we conducted a retrospective cohort study to examine patterns of ADF opioid use compared to non-ADF ER opioid use. Patients who initiated ADF and non-ADF ER opioids (18-64 years-old) were selected using both a traditional new user design (no opioid claims during the washout period, defined as six-months prior to ER opioid initiation) and a prevalent new user design (allowed non-ER opioid claims during the washout period and excluded the patients with no six-months eligibility prior to the first immediate-release (IR) opioid claim). Patient characteristics including demographics, medications (gabapentin, benzodiazepine, antidepressants, IR opioids), pain-related symptoms, and cancer were measured during the washout period for patients with ADF and non-ADF ER opioids. Results: Among eligible ER opioid initiators in Data A (N=330,728) and B (N=20,992), 31% and 34% initiated with ADF opioids, respectively. Among these patients, demographics were as follows (Data A and B): age [mean (SD)] = 49.4 (11.8) and 48.4 (11.8); male sex = 51.2% and 55.4%. Among patients with non-ADF ER opioids, demographics were as follows (Data A and Data B): age [mean (SD)] = 49.2 (11.4) and 47.8 (11.3); male sex = 45.8% and 50.4%. About 50% and 62% of patients with ADF opioids initiated with IR opioids, whereas 29%and 34% of patients with non-ADF ER opioids initiated with IR opioids in Data A and B, respectively. In both data sources, the prevalence of several types of pain was higher among patients with ADF opioids than in non-ADF ER group, including acute pain (Data A: 54.5% vs. 40.3%; Data B: 56.7% vs. 41.5%), arthritis pain (35.7% vs. 20.1%; 36.4% vs. 22.7%), and chronic pain (84.8% vs. 76.3%; 89.5% vs. 85.3%). The prevalence of use of medications and cancer was higher in patients with non-ADF ER opioids than in patients with ADF opioids in both data sources. Conclusions: Both data sources revealed differences in characteristics between patients with ADF and non-ADF ER opioids. The implications for research design include identifying appropriate comparator groups when examining ADF opioid use related outcomes

High Thermoelectric Performance in PbSe–NaSbSe2 Alloys from Valence Band Convergence and Low Thermal Conductivity

PbSe is an attractive thermoelectric material due to its favorable electronic structure, high melting point, and lower cost compared to PbTe. Herein, the hitherto unexplored alloys of PbSe with NaSbSe2 (NaPbmSbSem+2) are described and the most promising p‐type PbSe‐based thermoelectrics are found among them. Surprisingly, it is observed that below 500 K, NaPbmSbSem+2 exhibits unorthodox semiconducting‐like electrical conductivity, despite possessing degenerate carrier densities of ≈1020 cm−3. It is shown that the peculiar behavior derives from carrier scattering by the grain boundaries. It is further demonstrated that the high solubility of NaSbSe2 in PbSe augments both the thermoelectric properties while maintaining a rock salt structure. Namely, density functional theory calculations and photoemission spectroscopy demonstrate that introduction of NaSbSe2 lowers the energy separation between the L‐ and Σ‐valence bands and enhances the power factors under 700 K. The crystallographic disorder of Na+, Pb2+, and Sb3+ moreover provides exceptionally strong point defect phonon scattering yielding low lattice thermal conductivities of 1–0.55 W m‐1 K‐1 between 400 and 873 K without nanostructures. As a consequence, NaPb10SbSe12 achieves maximum ZT ≈1.4 near 900 K when optimally doped. More importantly, NaPb10SbSe12 maintains high ZT across a broad temperature range, giving an estimated record ZTavg of ≈0.64 between 400 and 873 K, a significant improvement over existing p‐type PbSe thermoelectrics.The high solubility of NaSbSe2 in PbSe is exploited to facilitate convergence of L‐ and Σ‐valence bands and to produce strong point defect phonon scattering. These processes yield enhanced power factors and low lattice thermal conductivity over ≈300–700 K, which together give NaPb10SbSe12 outstanding thermoelectric performance with a maximum ZT ≈ 1.4 at 873 K and ZTavg ≈0.64 over 400–873 K.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/151353/1/aenm201901377.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/151353/2/aenm201901377-sup-0001-S1.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/151353/3/aenm201901377_am.pd

Symptom burden and health-related quality of life in chronic kidney disease:A global systematic review and meta-analysis

BACKGROUND: The importance of patient-reported outcome measurement in chronic kidney disease (CKD) populations has been established. However, there remains a lack of research that has synthesised data around CKD-specific symptom and health-related quality of life (HRQOL) burden globally, to inform focused measurement of the most relevant patient-important information in a way that minimises patient burden. The aim of this review was to synthesise symptom prevalence/severity and HRQOL data across the following CKD clinical groups globally: (1) stage 1-5 and not on renal replacement therapy (RRT), (2) receiving dialysis, or (3) in receipt of a kidney transplant.METHODS AND FINDINGS: MEDLINE, PsycINFO, and CINAHL were searched for English-language cross-sectional/longitudinal studies reporting prevalence and/or severity of symptoms and/or HRQOL in CKD, published between January 2000 and September 2021, including adult patients with CKD, and measuring symptom prevalence/severity and/or HRQOL using a patient-reported outcome measure (PROM). Random effects meta-analyses were used to pool data, stratified by CKD group: not on RRT, receiving dialysis, or in receipt of a kidney transplant. Methodological quality of included studies was assessed using the Joanna Briggs Institute Critical Appraisal Checklist for Studies Reporting Prevalence Data, and an exploration of publication bias performed. The search identified 1,529 studies, of which 449, with 199,147 participants from 62 countries, were included in the analysis. Studies used 67 different symptom and HRQOL outcome measures, which provided data on 68 reported symptoms. Random effects meta-analyses highlighted the considerable symptom and HRQOL burden associated with CKD, with fatigue particularly prevalent, both in patients not on RRT (14 studies, 4,139 participants: 70%, 95% CI 60%-79%) and those receiving dialysis (21 studies, 2,943 participants: 70%, 95% CI 64%-76%). A number of symptoms were significantly (p &lt; 0.05 after adjustment for multiple testing) less prevalent and/or less severe within the post-transplantation population, which may suggest attribution to CKD (fatigue, depression, itching, poor mobility, poor sleep, and dry mouth). Quality of life was commonly lower in patients on dialysis (36-Item Short Form Health Survey [SF-36] Mental Component Summary [MCS] 45.7 [95% CI 45.5-45.8]; SF-36 Physical Component Summary [PCS] 35.5 [95% CI 35.3-35.6]; 91 studies, 32,105 participants for MCS and PCS) than in other CKD populations (patients not on RRT: SF-36 MCS 66.6 [95% CI 66.5-66.6], p = 0.002; PCS 66.3 [95% CI 66.2-66.4], p = 0.002; 39 studies, 24,600 participants; transplant: MCS 50.0 [95% CI 49.9-50.1], p = 0.002; PCS 48.0 [95% CI 47.9-48.1], p = 0.002; 39 studies, 9,664 participants). Limitations of the analysis are the relatively few studies contributing to symptom severity estimates and inconsistent use of PROMs (different measures and time points) across the included literature, which hindered interpretation.CONCLUSIONS: The main findings highlight the considerable symptom and HRQOL burden associated with CKD. The synthesis provides a detailed overview of the symptom/HRQOL profile across clinical groups, which may support healthcare professionals when discussing, measuring, and managing the potential treatment burden associated with CKD.PROTOCOL REGISTRATION: PROSPERO CRD42020164737.</p

Matching Study Design to Prescribing Intention: The Prevalent New User Design in Opioid Research

Background: In drug studies, research designs requiring no prior exposure to certain drug classes may restrict research on important populations. For example, currently marketed abuse-deterrent formulation (ADF) opioids are routinely used in patients with prior prescription opioid exposure. The traditional new user design excludes patients with prior exposure to prescription opioids, hence incident ADF users are not representative of the overall ADF user population. A prevalent new user design, wherein patients are prescribed similar treatments (or potential comparators) before starting the new treatment, likely better represents the intended ADF patient population. Objectives: To evaluate the appropriateness of new user versus prevalent new user design for estimating post-market effectiveness of ADFs and examine patterns of ADF initiation. Methods: We used pharmaceutical claims data from a large private insurer in North Carolina [USA] from 2009-2018. Included patients were new ADF users age 18-64 with 6 months of continuous enrollment prior to their first ADF claim. Incident users were identified as those with no prescription opioid claims in a 6-month washout period prior to ADF initiation. Prevalent new users were identified as those with non-ADF opioid claims during the 6 months before ADF initiation, so long as they also had a 6-month washout period of no opioid claims prior to first non-ADF opioid claim. We compared sample sizes by study design and described ADF utilization patterns. Results: We identified 8,841 eligible patients who initiated an ADF. Of these, 2,332 (26%) were classified as incident users, whereas 6,509 (74%) were prevalent new users and would be excluded in a traditional new user design. Most incident ADF users started with both an ADF and an immediate-release (IR) opioid concurrently (85%). Among prevalent new users, common ADF initiation patterns were: adding an ADF to an IR opioid regimen (43%), an immediate switch from IR opioids to an ADF (15%), and a delayed switch from IR opioids to an ADF (14%). Conclusions: Three-quarters of patients initiating ADFs had prior prescription opioid use and would be excluded in a traditional new user study design. A prevalent new user design would increase sample size and better capture clinically meaningful patients. These findings may apply to studies of other medications where prior exposure is a labeled prerequisite, such as higher dose ER opioids and second-line therapies. Future work will explore prevalent new user designs and consider nuances in ADF initiation such as immediate versus delayed switching by incorporating time-matching to address opioid tolerance

Mechanisms of Thermal Adaptation Revealed From the Genomes of the Antarctic Archaea Methanogenium frigidum and Methanococcoides burtonii

We generated draft genome sequences for two cold-adapted Archaea, Methanogenium frigidum and Methanococcoides burtonii, to identify genotypic characteristics that distinguish them from Archaea with a higher optimal growth temperature (OGT). Comparative genomics revealed trends in amino acid and tRNA composition, and structural features of proteins. Proteins from the cold-adapted Archaea are characterized by a higher content of noncharged polar amino acids, particularly Gin and Thr and a lower content of hydrophobic amino acids, particularly Leu. Sequence data from nine methanogen genomes (OGT 15degrees-98degreesC) were used to generate IIII modeled protein structures. Analysis of the models from the cold-adapted Archaea showed a strong tendency in the solvent-accessible area for more Gin, Thr, and hydrophobic residues and fewer charged residues. A cold shock domain (CSD) protein (CspA homolog) was identified in M. frigidum, two hypothetical proteins with CSD-folds in M. burtonii, and a unique winged helix DNA-binding domain protein in M. burtonii. This suggests that these types of nucleic acid binding proteins have a critical role in cold-adapted Archaea. Structural analysis of tRNA sequences from the Archaea indicated that GC content is the major factor influencing tRNA stability in hyperthermophiles, but not in the psychrophiles, mesophiles or moderate thermophiles. Below an OGT of 60degreesC, the GC content in tRNA was largely unchanged, indicating that any requirement for flexibility of tRNA in psychrophiles is mediated by other means. This is the first time that comparisons have been performed with genome data from Archaea spanning the growth temperature extremes. from psychrophiles to hyperthermophile

Targeted prevention of common mental health disorders in university students: randomised controlled trial of a transdiagnostic trait-focused web-based intervention

Background: A large proportion of university students show symptoms of common mental disorders, such as depression, anxiety, substance use disorders and eating disorders. Novel interventions are required that target underlying factors of multiple disorders.&lt;p&gt;&lt;/p&gt; Aims: To evaluate the efficacy of a transdiagnostic trait-focused web-based intervention aimed at reducing symptoms of common mental disorders in university students.&lt;p&gt;&lt;/p&gt; Method: Students were recruited online (n = 1047, age: M = 21.8, SD = 4.2) and categorised into being at high or low risk for mental disorders based on their personality traits. Participants were allocated to a cognitive-behavioural trait-focused (n = 519) or a control intervention (n = 528) using computerised simple randomisation. Both interventions were fully automated and delivered online (trial registration: ISRCTN14342225). Participants were blinded and outcomes were self-assessed at baseline, at 6 weeks and at 12 weeks after registration. Primary outcomes were current depression and anxiety, assessed on the Patient Health Questionnaire (PHQ9) and Generalised Anxiety Disorder Scale (GAD7). Secondary outcome measures focused on alcohol use, disordered eating, and other outcomes.&lt;p&gt;&lt;/p&gt; Results: Students at high risk were successfully identified using personality indicators and reported poorer mental health. A total of 520 students completed the 6-week follow-up and 401 students completed the 12-week follow-up. Attrition was high across intervention groups, but comparable to other web-based interventions. Mixed effects analyses revealed that at 12-week follow up the trait-focused intervention reduced depression scores by 3.58 (p&#60;.001, 95%CI [5.19, 1.98]) and anxiety scores by 2.87 (p = .018, 95%CI [1.31, 4.43]) in students at high risk. In high-risk students, between group effect sizes were 0.58 (depression) and 0.42 (anxiety). In addition, self-esteem was improved. No changes were observed regarding the use of alcohol or disordered eating.&lt;p&gt;&lt;/p&gt; Conclusions This study suggests that a transdiagnostic web-based intervention for university students targeting underlying personality risk factors may be a promising way of preventing common mental disorders with a low-intensity intervention

A large-scale automated radio telemetry network for monitoring movements of terrestrial wildlife in Australia

Technologies for remotely observing animal movements have advanced rapidly in the past decade. In recent years, Australia has invested in an Integrated Marine Ocean Tracking (IMOS) system, a land ecosystem observatory (TERN), and an Australian Acoustic Observatory (A2O), but has not established movement tracking systems for individual terrestrial animals across land and along coastlines. Here, we make the case that the Motus Wildlife Tracking System, an open-source, rapidly expanding cooperative automated radio-tracking global network (Motus, https://motus.org) provides an unprecedented opportunity to build an affordable and proven infrastructure that will boost wildlife biology research and connect Australian researchers domestically and with international wildlife research. We briefly describe the system conceptually and technologically, then present the unique strengths of Motus, how Motus can complement and expand existing and emerging animal tracking systems, and how the Motus framework provides a much-needed central repository and impetus for archiving and sharing animal telemetry data. We propose ways to overcome the unique challenges posed by Australia’s ecological attributes and the size of its scientific community. Open source, inherently cooperative and flexible, Motus provides a unique opportunity to leverage individual research effort into a larger collaborative achievement, thereby expanding the scale and scope of individual projects, while maximising the outcomes of scant research and conservation funding